---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-008429"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:10:52.116893+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics reports FY2024 revenue $35.6M, net loss $1.52/sh; cash runway into 2027

## Summary
- FY2024 revenue $35.6M (vs $20.8M in FY2023); net loss $105.3M ($1.52/sh) vs $132.5M ($2.67).
- Cash $267.3M at Dec 31, 2024; expected to fund operations into 2027.
- Cemsidomide dose escalation continues; next-phase trials expected to start in early 2026.
- CFT1946 Phase 1/2 progressing; data in melanoma and CRC expected H2 2025.
- Appointed Steve Hoerter to board; initiated CFT8919 Phase 1 in Greater China with Betta.

## SEC filing metadata
- accession: 0001628280-25-008429
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828025008429/0001628280-25-008429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828025008429/cccc-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-008429
- JSON: https://secwatch.observer/filing/0001628280-25-008429.json
- Plain text: https://secwatch.observer/filing/0001628280-25-008429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.